1-4 of 4
Christopher S. Lathan
Close
Sort by
Journal Articles

Alignment of Later Phase Clinical Trial Eligibility Criteria with Drug Safety in Acute Leukemia: Minimizing Unnecessary Patient Risk and Exclusion

Elizabeth Warner, Thomas P Walsh, Daniel J. DeAngelo, Christopher S. Lathan, Gregory A Abel, Andrew Hantel
Journal: Blood
Blood (2023) 142 (Supplement 1): 263.
https://doi.org/10.1182/blood-2023-174880
Published: 2023
Journal Articles

Development of a Real-Time Dashboard Characterizing Acute Leukemia Clinical Trial Enrollment Diversity at the Practice, Investigator, and Individual Clinician Level

Andrew Hantel, Kelsey Y Li, Saima Awan, Thomas P Walsh, Emerald D Littlejohn, Daniel J. DeAngelo, Christopher S. Lathan, Gregory A Abel
Journal: Blood
Blood (2023) 142 (Supplement 1): 132.
https://doi.org/10.1182/blood-2023-174899
Published: 2023
Journal Articles

Access and Treatment Equity across the Comprehensive Cancer Center Catchment Area: Targets for Disparities Remediation in Acute Leukemia Research Participation

Andrew Hantel, Marlise R. Luskin, Timothy R. Rebbeck, Andrew M. Brunner, Dillon D. Clancy, Richard M. Stone, Daniel J DeAngelo, Christopher S. Lathan, Gregory A. Abel
Journal: Blood
Blood (2022) 140 (Supplement 1): 926–927.
https://doi.org/10.1182/blood-2022-166568
Published: 2022
Journal Articles

Stakeholder Perceptions of Barriers to Diverse Acute Myeloid Leukemia Clinical Trial Enrollment at Comprehensive Cancer Centers

Andrew Hantel, Jane Roberts, Anna Revette, Christopher S. Lathan, Gregory A. Abel
Journal: Blood
Blood (2021) 138 (Supplement 1): 3014.
https://doi.org/10.1182/blood-2021-147830
Published: 2021